Single-agent irinotecan as second-line treatment for advanced gastric cancer
No Thumbnail Available
Date
2003
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Sage Publications
Abstract
Aim. To investigate the activity and toxicity of irinotecan (CPT-11) as a single agent in patients with advanced gastric cancer after failure of previous 5-fluorouracil-based combination chemotherapy. Patients and methods: Sixteen patients with advanced gastric received CPT-11, 350 mg/m2 every 21 days. The median age of the patients was 54.6 years; ECOG performance status was 0-1 in 14 patients and 2 in 2 patients. Dominant metastatic sites included liver, lung, lymph nodes and peritoneum. Results: No complete response was observed. Two patients (12.5%) achieved a partial response to treatment. One patient (6.25%) had a minor response. Ten patients (62.5%) had progressive disease on therapy, and 3 patients (18.75%) had stable disease. The median survival of all 16 patients was 5 months. Grade 3 neutropenia was observed in 3 patients (18.75%), grade 4 thrombocytopenia in 1 patient (6.25%), and grade 3 anemia in 1 patient (6.25%). Three patients (18.75%) suffered from grade 3 diarrhea. Conclusions: CPT-11 is moderately active and a well-tolerated regimen for selected advanced gastric cancer patients who experience disease progression after receiving first-line treatment.
Description
Keywords
Oncology, Gastric cancer, Irinotecan, Second-line chemotherapy, Supportive care, Phase-II, Methotrexate, Carboplatin, Paclitaxel, Cisplatin
Citation
Kanat, O. vd. (2003). “Single-agent irinotecan as second-line treatment for advanced gastric cancer”. Tumori Journal, 89(4), 405-407.